NewsBenzingaResMed prevé un BPA ajustado para el ejercicio fiscal 2027 de $12.00-$12.25 frente a $12.09 estimado; prevé ventas de $5.750B-$5.850B frente a $5.814B estimado ResMed prevé un BPA ajustado para el ejercicio fiscal 2027 de $12.00-$12.25 frente a $12.09 estimado; prevé ventas de $5.750B-$5.850B frente a $5.814B estimado Benzinga 2026.10.29 21:31 (GMT+0) Open on Benzinga Other news Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders ‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors Analysis: Bitcoin's 12% Weekly Drop and Break Below 200-Week Moving Average — All Three Similar Historical Cases Rose Three Months Later Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead Binance to Remove 5 Spot Trading Pairs Including GAS/TRY and HBAR/BNB on November 20 Micron Technology (MU) Stock Is Trending After Hours: Here's Why
Paytaca: Backend Systems Attacked but User Funds and Private Keys Unaffected, Warns Against Interacting with Suspicious Orders
‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors
Analysis: Bitcoin's 12% Weekly Drop and Break Below 200-Week Moving Average — All Three Similar Historical Cases Rose Three Months Later
Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead